|
XOLAIR
Xolair
Xolair is an injectable drug used to treat asthma and is approved to treat adults and adolescents with moderate to severe persistent asthma.
The Food and Drug Administration has demanded that Genentech Inc. change the drug's information sheet to carry the strongest warning possible about the Xolair's risk of anaphylaxis.
Anaphylaxis is a severe allergic reaction that could occur as late as 24 hours after patients take any amount of the drug, and can be life-threatening.
Symptoms of anaphylactic shock include trouble breathing, dizziness and swelling in the mouth and throat.
Doctors have been warned that they should observe patients for at least two hours after injecting them with Xolair, and patients are urged to be prepared to treat themselves for any of the symptoms.
Based on reports from approximately 39,500 patients, anaphylaxis following Xolair treatment occurred in at least 0.1% of treated people.
Even patients who did not react to a previous Xolair injection, may suffer from anaphylaxis.
XOLAIR NEWS
The FDA has required Genentech to put it's most severe "black box" warning regarding potentially life-threatening allergic reaction (anaphylaxis) on the label of its asthma drug Xolair.
(Jul-03-07) WEB MD: XOLAIR
On February 21st 2007, the FDA recommended that Genentech Inc., the makers of Xolair, include a black box alert on the product packaging that warns of a severe, and potentially life-threatening allergic reaction. (Apr-21-07) LAS: XOLAIR
Patients being treated with Xolair should be warned about the signs and symptoms of anaphylaxis and their chance of developing delayed anaphylaxis following Xolair treatment. (Feb-21-07) PHARMALIVE: XOLAIR
Submit Your Complaint
If you or a loved one has taken Xolair and subsequently experienced anaphylaxis, you may be entitled to compensation in a class action lawsuit. Please fill out the form to the right to send your complaint to a lawyer who will review your claim at no cost or obligation.
|
 |
|
